Intellia Therapeutics announced it has temporarily paused its MAGNITUDE and MAGNITUDE-2 Phase III clinical trials of nex-z for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN), respectively. 

The action follows a report of Grade 4 liver transaminases and increased total bilirubin in a patient who was dosed with nex-z in the MAGNITUDE trial, meeting the trial’s protocol-defined pausing criteria.  

The patient was hospitalised, is being closely monitored and is receiving medical intervention. Intellia says it is consulting with experts, considering potential risk mitigation strategies and engaging with regulatory authorities. 

“In line with our commitment to patient safety, we have taken immediate action to temporarily pause enrolment in MAGNITUDE and MAGNITUDE-2 as we investigate this recent event,” said Intellia President and Chief Executive Officer John Leonard. “As we focus on ensuring the health of this patient, we also are engaging with regulatory authorities and other stakeholders globally to develop a strategy to resume enrolment as soon as appropriate.” 

More than 650 patients with ATTR-CM are enrolled in MAGNITUDE, and 47 patients with ATTR-PN are enrolled in MAGNITUDE-2. Over 450 of these patients are estimated to have been dosed with nex-z. 

Nex-z is based on CRISPR/Cas9 gene editing technology, and has the potential to become the first one-time treatment for transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) and/or polyneuropathy (ATTR-PN).  

It is designed to inactivate the TTR gene that encodes for the transthyretin (TTR) protein. Interim Phase I clinical data showed the administration of nex-z led to consistent, deep and long-lasting TTR reduction.  

Nex-z has received an Orphan Drug and RMAT Designation from the US Food and Drug Administration (FDA) and an Orphan Drug Designation (ODD) from the European Commission.  

Intellia leads development and commercialization of nex-z as part of a collaboration with Regeneron Pharmaceuticals.

Diana Turner, Deputy Editor, DDW